Expressing Personalized Tumor Antigens Study

Related Clinical Trial
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab A Study of RC48-ADC in Patients With HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Multimodal Spectroscopy to Detect Urothelial Cancer in Urine A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas A Study of ICP-192 in Patients With Advanced Solid Tumors Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Fear of Cancer Recurrence in Genitourinary Cancer Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV A Multicenter Cancer Biospecimen Collection Study Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers A Study of ZN-c3 in Participants With Solid Tumors Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors GEN1046 Safety Trial in Patients With Malignant Solid Tumors Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Study of the CD40 Agonistic Monoclonal Antibody APX005M A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer B-Receptor Signaling in Cardiomyopathy Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Development of Diagnostics and Treatment of Urological Cancers Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response A Study of Personalized Neoantigen Cancer Vaccines A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients A Study Evaluating MM-310 in Patients With Solid Tumors MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Water Versus Saline as Irrigation Fluid for Ureteroscopy A Study of a Personalized Neoantigen Cancer Vaccine Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer Prospective Trial for Examining Hematuria Using Computed Tomography Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial Expressing Personalized Tumor Antigens Study Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Relationship of Ochratoxin A to Upper Urologic Cancers Patient-reported Outcomes in Bladder Cancer Confocal Laser Endomicroscopy in the Lower Urinary Tract Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer Derazantinib and Atezolizumab in Patients With Urothelial Cancer Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer Predictive Factorsfor Final Pathologic Ureteral Sections The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies The Cxbladder Hematuria Clinical Utility Study Cabozantinib for Advanced Urothelial Cancer A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations PF-03446962 in Relapsed or Refractory Urothelial Cancer Improve Checkpoint-blockade Response in Advanced Urothelial Cancer Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Efficacy and Safety of UGN-101 in Recurrent Patients Prospective Multicentric Evaluation of a Bladder Preservation Strategy Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder Evaluation of NanoDoce® in Participants With Urothelial Carcinoma Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma Single Agent Abraxane as Second Line Therapy in Bladder Cancer KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer JAVLOR® Online Non-Interventional Trial A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Alisertib in Chemotherapy-pretreated Urothelial Cancer Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence Study of Sitravatinib and Nivolumab in Urothelial Carcinoma Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence Biological Effect of Vitamin D in Patients With Urothelial Carcinoma Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy The Cxbladder Monitoring Study Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Locally Advanced and Metastatic Urothelial Carcinoma Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Application of UCAD for Diagnosing Urothelial Carcinoma. A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC Weekly TP-HDFL in the Treatment of Advanced TCC Detecting Transitional Cell Carcinoma From Haematuria Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma Vasculogenic Mimicry in Urothelial Carcinoma Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma DNA Methylation and Urothelial Carcinoma JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin DNA Methylation and Arsenic-associated Urothelial Carcinoma Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Brief Title

Expressing Personalized Tumor Antigens Study

Official Title

A Phase 1 Dose-Escalation Study of ADXS NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Brief Summary

      This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in
      combination with pembrolizumab in subjects with select advanced or metastatic solid tumors.
      This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy
      phase (Part C).
    

Detailed Description

      Mutation-derived tumor antigens, which are often unique to each patient's tumor, represent a
      new source of targets for cancer immunotherapy. These mutations, which arise during
      tumorigenesis, are expressed only by the tumor and, as such, may be recognized as newly
      formed antigens, or neoantigens, by the patient's T cells. The lack of expression of
      patient-specific tumor mutations in nonmalignant cells suggests that vaccines targeting these
      tumor mutations have a low risk of autoimmunity and may represent a safer therapeutic
      approach than many of those currently available. The development of a Listeria monocytogenes
      (Lm)-based vaccine that expresses these patient-specific tumor antigens and that activates
      tumor-killing T cells has the potential to be a highly effective form of immunotherapy. In
      addition, the Lm platform, because it mediates tumor control through multiple mechanisms, may
      exhibit more robust anti-tumor activity than other vaccine platforms. Thus, the targeting of
      patient-specific mutation-derived tumor antigens and the concurrent stimulation of host
      immunity provides a rational approach for boosting anti-tumor immunity, as monotherapy and in
      combination with anti-PD-1 inhibitors.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Incidence of Treatment-Emergent Adverse Events

Secondary Outcome

 Initial signs of clinical activity

Condition

Colon Cancer Metastatic

Intervention

ADXS-NEO

Study Arms / Comparison Groups

 Part A
Description:  Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.
Two dose levels of ADXS-NEO will be explored: 1 x 10 to the 9th power and 1 x 10 to the 8th power colony forming unit (CFU).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

5

Start Date

June 7, 2018

Completion Date

January 31, 2022

Primary Completion Date

January 31, 2022

Eligibility Criteria

        Inclusion:

          1. ≥18 years of age on the day of signing informed consent.

          2. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          3. Screening tumor biopsy must be adequate for the identification of NSMs by whole exome
             sequencing and for the development of ADXS-NEO. Biopsies may be repeated for subjects
             whose Screening biopsies are found to be inadequate for the development of ADXS-NEO.
             Biopsy should be excisional, incisional or core needle. Fine needle aspiration is
             generally inadequate.

          4. Subject population for Part A (ADXS-NEO monotherapy) is as follows:

               1. Histological or cytological diagnosis of metastatic CRC excluding known MSI-high
                  sub-types, metastatic SCCHN or metastatic NSCLC that have progressed or have
                  become intolerant to standard therapy, and whose disease may allow management
                  with other available therapies (or a treatment break, if appropriate) for up to
                  approximately 12 weeks following Screening tumor biopsy. More than one form of
                  anti-tumor therapy is allowed during this interval.

               2. For metastatic CRC, up to 4 lines of approved therapy in the advanced or
                  metastatic setting are allowed, including approved antibody and targeted agent
                  therapy. Subjects may be eligible if they have received additional lines of
                  therapy upon discussion with and approval by the Sponsor. Subjects are excluded
                  if they are known to have MSI-high tumors. If the status of microsatellite
                  stability is not known, subjects are eligible. The determination of
                  microsatellite stability for CRC may be made by local testing on any available
                  tissue prior to study entry.

               3. For metastatic SCCHN, up to 2 lines of approved therapy in the advanced or
                  metastatic setting are allowed, including approved antibody therapy and
                  immunotherapy if eligible. Subjects may be eligible if they have received
                  additional lines of therapy upon discussion with and approval by the Sponsor.

               4. For metastatic NSCLC, up to 3 lines of approved therapy in the advanced or
                  metastatic setting are allowed, including approved antibodies, targeted agents
                  and immunotherapy if eligible. Tumors harboring squamous and/or non-squamous
                  histologies are eligible. Tumors harboring squamous and/or non-squamous
                  histologies with neuroendocrine or small cell components may be eligible upon
                  discussion with and approval by the Sponsor.

               5. Prior exposure to immunotherapy including, but not limited to, anti-PD1 or
                  anti-PDL1 antibodies is allowed but not required. Subjects who received prior
                  treatment with such agents must meet the following criteria: (a) Full resolution
                  of prior checkpoint inhibitor-related adverse events and no treatment for these
                  adverse events for at least 3 weeks prior to the first infusion of ADXS-NEO; and
                  (b) no history of severe immune related adverse events (irAE) from prior exposure
                  to checkpoint inhibitors. Severe irAEs are defined as any CTCAE Grade 4 toxicity
                  requiring treatment with corticosteroids or Grade 3 toxicity requiring
                  corticosteroid treatment (greater than 10 mg/day prednisone or equivalent dose)
                  for greater than 12 weeks.

          5. Subject population for Part B and Part C (ADXS-NEO + pembrolizumab) is as follows:

               1. Histological or cytological diagnosis of NSCLC, SCCHN, urothelial carcinoma, or
                  melanoma.

               2. Subject has received, and then progressed or been intolerant to up to 3 lines of
                  prior therapy in the advanced or metastatic setting, including approved
                  chemotherapy, targeted therapy, immunotherapy and antibody therapy, if eligible.
                  Subjects who have received >3 lines of prior therapy may be eligible upon
                  discussion with and approval by the Sponsor.

               3. For NSCLC: subjects with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as
                  determined by an FDA-approved test are eligible, with disease progression on or
                  after platinum-containing chemotherapy. Subjects with EGFR or ALK genomic tumor
                  aberrations should have disease progression on FDA-approved therapy for these
                  aberrations prior to enrolment.

               4. For SCCHN: subjects with recurrent or metastatic SCCHN with disease progression
                  on or after platinum-containing chemotherapy are eligible.

               5. For urothelial carcinoma:

             i. Subjects with locally advanced or metastatic urothelial carcinoma who are not
             eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1
             [Combined Positive Score (CPS) ≥10] as determined by an FDA-approved test, or subjects
             who are not eligible for any platinum-containing chemotherapy regardless of PD-L1
             status, are eligible.

             ii. Subjects with locally advanced or metastatic urothelial carcinoma who have disease
             progression during or following platinum-containing chemotherapy or within 12 months
             of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, are
             eligible.

             f. For melanoma: subjects with unresectable or metastatic melanoma are eligible.

          6. Has evaluable or measurable disease for response assessment per RECIST v1.1.

          7. Has adequate organ function as defined in Appendix 2 (Eligibility criteria).

          8. Has no major existing comorbidities or medical conditions that will preclude therapy
             in the view of the Investigator.

          9. Baseline blood oxygen saturation on room air of > 95%

         10. Resolution to Grade ≤1 by the National Cancer Institute Common Terminology Criteria
             for Adverse Events, Version 4.03 (NCI-CTCAE v 4.03) of all clinically significant
             toxic effects of prior anti-tumor therapy within 3 weeks of first dose of study
             treatment except for alopecia.

         11. A female subject is eligible to participate if she is not pregnant (see Appendix 5),
             not breastfeeding, and at least one of the following conditions applies:

               1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR

               2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the
                  study treatment period and for at least 120 days after the last dose of study
                  treatment.

         12. Female subjects of childbearing potential must have a negative urine or serum
             pregnancy test within 72 hours prior to receiving any dose of ADXS-NEO. If the urine
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be
             required.

         13. A male subject is eligible to participate if he agrees to follow the contraceptive
             guidance during the study treatment period and for at least 120 days after the last
             dose of study treatment.

         14. Provide written informed consent for the trial including mandatory biopsy of
             accessible lesion(s) during Screening (Parts A, B and C), and mandatory on-treatment
             biopsy (Parts A and B; if there is no complete resolution of lesions and if the safety
             risk for biopsy remains acceptable).

        Exclusion:

          1. Has a newly diagnosed tumor and a curative treatment option or approved therapy is
             available.

          2. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
             Subjects with previously treated brain metastases may participate provided that they
             are stable (without evidence of progression by imaging for at least 4 weeks prior to
             the first dose of trial treatment and any neurologic symptoms have returned to
             baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to first dose of ADXS-NEO (Part A) or pembrolizumab
             (Part B and Part C). If a subject does not meet these criteria, the subject may be
             eligible upon discussion and agreement between the Sponsor and Investigator based upon
             the subject's specific case.

          3. Any active autoimmune disease or a documented history of autoimmune disease, or
             history of a syndrome that required systemic steroids or immunosuppressive
             medications, except for subjects with ≤ Grade 2 vitiligo or resolved childhood
             asthma/atopy or uncomplicated dermatitis.

          4. History of recently (within previous 12 months) active diverticulitis, symptomatic
             peptic ulcer disease, colitis, inflammatory bowel disease or any gastrointestinal
             diseases that, in the opinion of the Investigator and Sponsor's medical monitor would
             pose a risk to the subject safety.

          5. History of other active malignancy for < 2 years prior to enrollment. Basal cell
             carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cancer that has
             undergone potentially curative therapy or is felt by the Investigator to be at low
             risk for recurrence is allowed.

          6. History or evidence of cardiovascular risk including any of the following:

               1. History or evidence of clinically significant arrhythmias (ventricular
                  fibrillation, ventricular tachycardia, supraventricular tachycardia, atrial
                  tachycardia/flutter, atrial fibrillation with rapid ventricular response, second
                  or third degree atrioventricular block, and sick sinus syndrome).

                  Exception: Subjects with controlled atrial fibrillation for >30 days prior to
                  enrollment are eligible. Controlled atrial fibrillation is defined as atrial
                  fibrillation with no ventricular response which requires no change in
                  medication/dosage or addition of new medication or hospital admission within 30
                  days prior to enrollment.

               2. History of acute coronary syndromes (e.g., myocardial infarction and unstable
                  angina) and/or coronary angioplasty within 6 months prior to enrollment.

               3. History or evidence of ≥ Class II congestive heart failure as defined by New York
                  Heart Association (NYHA).

               4. Chronic hypertension (defined as a systolic blood pressure >140 mm Hg and/or
                  diastolic blood pressure >90 mm Hg which cannot be controlled by
                  anti-hypertensive therapy).

               5. Subjects with intra-cardiac defibrillators.

               6. Abnormal cardiac valve morphology (≥Grade 2). Subjects with grade 1 abnormalities
                  can be entered on study. Subjects with moderate valvular thickening should not be
                  entered on study. History of arterial thrombosis (e.g., stroke or transient
                  ischemic attack) in the past 3 months.

          7. Psychiatric or substance abuse disorders that would interfere with cooperation with
             the requirements of the trial.

          8. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the Screening visit(s) through 120 days
             after the last dose of study treatment.

          9. Active infection requiring systemic therapy or is dependent on or currently receiving
             antibiotics that cannot be discontinued before dosing. (NOTE: Subjects who discontinue
             an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of
             antibiotic before receiving ADXS-NEO (Part A) or pembrolizumab (Part B and Part C).

         10. Treatment with immune modulators including, but not limited to, chronic
             immunosuppressive dose of corticosteroid (>10 mg/day of prednisone or equivalent),
             cyclosporine, or tacrolimus within 4 weeks prior to enrollment. If the subject was
             receiving corticosteroids, taper or discontinuation must be completed at least 1 week
             prior to the first dose of ADXS-NEO (Part A) or pembrolizumab (Part B and Part C).
             Occasional topical corticosteroids and/or inhaled corticosteroids are allowed for a
             dose equivalency of ≤10 mg prednisone taken orally per week.

         11. Known allergy to any component of the study treatment formulation(s).

         12. Known history of human immunodeficiency virus (HIV).

         13. Known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

         14. Implanted medical device(s) that pose a high risk for colonization and/or cannot be
             easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers,
             defibrillators, orthopedic screw[s], metal plate[s], bone graft[s], or other
             implant[s]). NOTE: More common devices and prosthetics that include arterial and
             venous stents, dental and breast implants, urinary catheters, and venous access
             devices (e.g., Port-a-Cath or Mediport) are permitted. The Sponsor must be contacted
             prior to consenting any participant who has any other device and/or implant.

         15. Contraindication (i.e., documented sensitivity/allergy) to
             trimethoprim/sulfamethoxazole and ampicillin.

         16. Contraindication to non-steroidal anti-inflammatory drugs (NSAIDs).

         17. In the opinion of the investigator, participant has rapidly progressing disease, OR
             has life expectancy <6 months, OR would be unable to receive at least one dose of
             ADXS-NEO.

             Prior/Concomitant Therapy

         18. Monoclonal antibody or biologic therapy within 5 half-lives or 28 days, whichever is
             shorter, prior to first dose of ADXS-NEO (Part A) or pembrolizumab (Part B and Part
             C). Subjects undergoing therapy with pembrolizumab at the time of Screening (Part B)
             may continue pembrolizumab without the above-mentioned washout period if stable.

         19. Received anticancer chemotherapy, surgical treatment, and/or radiation therapy (except
             palliative radiation therapy for disease-related pain in consultation with the
             Sponsor's medical monitor) within 3 weeks of first dose of ADXS-NEO (Part A) or
             pembrolizumab (Part B and Part C).

         20. Because of a possible interaction between attenuated Lm and PI3K inhibitor (may be
             directly involved in regulation of TNFα production and enhance Lm virulence)
             (Hochdorfer 2011; Smith, 2007; Sonje 2010), subjects receiving a PI3K or TNFα
             inhibitor within 3 weeks of first dose of study treatment, or are expected to receive
             such agents at any time during the treatment period, are excluded.

         21. Received a live vaccine within 30 days prior to the first dose of ADXS-NEO (Part A) or
             pembrolizumab (Part B and Part C).

         22. Major surgery, including surgery for a new artificial implant and/or medical device,
             which is permitted by the protocol, within 6 weeks prior to initiation of ADXS-NEO
             (Part A) or pembrolizumab (Part B and Part C). NOTE: All toxicities and/or
             complications must have recovered to baseline or Grade 1 prior to the initiation of
             study treatment. Consult with the Sponsor prior to enrolling participants who recently
             had major surgery or who have a new artificial implant, and/or devices.

             Prior/Concurrent Clinical Study Experience

         23. Currently participating in or has participated in a study of an investigational agent
             or is using an investigational device within 3 weeks of enrollment.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03265080

Organization ID

ADXS-NEO-02


Responsible Party

Sponsor

Study Sponsor

Advaxis, Inc.


Study Sponsor

, , 


Verification Date

August 2020